Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trialnews2026-08-20T14:33:30+00:00August 20th, 2026|Endpoints News|
Amgen cans its TScan partnership; Amylyx reveals $350M offeringnews2026-08-19T14:43:16+00:00August 19th, 2026|Endpoints News|
Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse mergernews2026-08-17T14:36:05+00:00August 17th, 2026|Endpoints News|
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlontanews2026-08-14T14:10:55+00:00August 14th, 2026|Endpoints News|
Zealand’s royalty deal; Khartis raises money for TED drugnews2026-08-13T14:19:46+00:00August 13th, 2026|Endpoints News|
AbCellera, Silence and InduPro all raise significant fundingnews2026-08-12T15:25:55+00:00August 12th, 2026|Endpoints News|
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75Mnews2026-08-11T14:44:13+00:00August 11th, 2026|Endpoints News|
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 winnews2026-08-10T15:33:02+00:00August 10th, 2026|Endpoints News|
BioMarin discontinues rare disease drug; CSL and Arcturus split upnews2026-08-07T15:08:24+00:00August 7th, 2026|Endpoints News|
Sarepta pushes back Elevidys timeline; Emergent lays off 90 staffersnews2026-08-06T13:55:00+00:00August 6th, 2026|Endpoints News|
